These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26015513)

  • 21. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
    Boghaert ER; Sridharan L; Armellino DC; Khandke KM; DiJoseph JF; Kunz A; Dougher MM; Jiang F; Kalyandrug LB; Hamann PR; Frost P; Damle NK
    Clin Cancer Res; 2004 Jul; 10(13):4538-49. PubMed ID: 15240546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
    Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models.
    Furuuchi K; Rybinski K; Fulmer J; Moriyama T; Drozdowski B; Soto A; Fernando S; Wilson K; Milinichik A; Dula ML; Tanaka K; Cheng X; Albone E; Uenaka T
    Cancer Sci; 2021 Jun; 112(6):2467-2480. PubMed ID: 33756060
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Kasten BB; Oliver PG; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
    Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
    Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
    Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
    Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
    Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
    Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.
    Cazet AS; Hui MN; Elsworth BL; Wu SZ; Roden D; Chan CL; Skhinas JN; Collot R; Yang J; Harvey K; Johan MZ; Cooper C; Nair R; Herrmann D; McFarland A; Deng N; Ruiz-Borrego M; Rojo F; Trigo JM; Bezares S; Caballero R; Lim E; Timpson P; O'Toole S; Watkins DN; Cox TR; Samuel MS; Martín M; Swarbrick A
    Nat Commun; 2018 Jul; 9(1):2897. PubMed ID: 30042390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
    Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy.
    Sulaiman A; McGarry S; El-Sahli S; Li L; Chambers J; Phan A; Côté M; Cron GO; Alain T; Le Y; Lee SH; Liu S; Figeys D; Gadde S; Wang L
    Mol Cancer Ther; 2019 Oct; 18(10):1755-1764. PubMed ID: 31308079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer.
    Kurani H; Razavipour SF; Harikumar KB; Dunworth M; Ewald AJ; Nasir A; Pearson G; Van Booven D; Zhou Z; Azzam D; Wahlestedt C; Slingerland J
    Clin Cancer Res; 2022 May; 28(9):1948-1965. PubMed ID: 35135840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition.
    Shee K; Wells JD; Ung M; Hampsch RA; Traphagen NA; Yang W; Liu SC; Zeldenrust MA; Wang L; Kalari KR; Yu J; Boughey JC; Demidenko E; Kettenbach AN; Cheng C; Goetz MP; Miller TW
    Clin Cancer Res; 2020 Jan; 26(1):159-170. PubMed ID: 31558472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
    Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
    Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.
    Gómez-Miragaya J; Palafox M; Paré L; Yoldi G; Ferrer I; Vila S; Galván P; Pellegrini P; Pérez-Montoyo H; Igea A; Muñoz P; Esteller M; Nebreda AR; Urruticoechea A; Morilla I; Pernas S; Climent F; Soler-Monso MT; Petit A; Serra V; Prat A; González-Suárez E
    Stem Cell Reports; 2017 May; 8(5):1392-1407. PubMed ID: 28457887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
    Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
    Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
    [No Abstract]   [Full Text] [Related]  

  • 37. A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.
    Savage P; Blanchet-Cohen A; Revil T; Badescu D; Saleh SMI; Wang YC; Zuo D; Liu L; Bertos NR; Munoz-Ramos V; Basik M; Petrecca K; Asselah J; Meterissian S; Guiot MC; Omeroglu A; Kleinman CL; Park M; Ragoussis J
    Cell Rep; 2017 Oct; 21(5):1140-1149. PubMed ID: 29091754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.
    Toosi BM; El Zawily A; Truitt L; Shannon M; Allonby O; Babu M; DeCoteau J; Mousseau D; Ali M; Freywald T; Gall A; Vizeacoumar FS; Kirzinger MW; Geyer CR; Anderson DH; Kim T; Welm AL; Siegel P; Vizeacoumar FJ; Kusalik A; Freywald A
    Oncogene; 2018 Jul; 37(30):4073-4093. PubMed ID: 29700392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.
    Yu J; Qin B; Moyer AM; Nowsheen S; Liu T; Qin S; Zhuang Y; Liu D; Lu SW; Kalari KR; Visscher DW; Copland JA; McLaughlin SA; Moreno-Aspitia A; Northfelt DW; Gray RJ; Lou Z; Suman VJ; Weinshilboum R; Boughey JC; Goetz MP; Wang L
    J Clin Invest; 2018 Jun; 128(6):2376-2388. PubMed ID: 29708513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.
    Bernier C; Soliman A; Gravel M; Dankner M; Savage P; Petrecca K; Park M; Siegel PM; Shore GC; Roulston A
    Anticancer Drugs; 2018 Sep; 29(8):774-785. PubMed ID: 29878901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.